On June 30, 2023, HORIZON THERAPEUTICS PUBLIC ($NASDAQ:HZNP) announced their Q2 FY2023 earnings results. Their total revenue for the period came in at USD 945.0 million, representing a 7.8% increase over the same period in the previous year. Net income rose by an impressive 108.4% year-over-year, totaling USD 127.1 million.
The company’s stock opened at $102.6 and closed at $104.1, representing a 2.9% increase from their previous closing price of $101.1. This was a positive development for investors, as it shows that the company is continuing to perform well despite the current economic climate. Overall, Horizon Therapeutics showed strong results in the second quarter of FY2023, with their share price increasing significantly in response. Investors will be hopeful that the company can continue to outperform expectations and provide positive returns in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for HZNP. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for HZNP. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for HZNP. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for HZNP are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an analysis of HORIZON THERAPEUTICS PUBLIC, and we are pleased to share the results of our wellbeing assessment. Our Star Chart revealed that HORIZON THERAPEUTICS PUBLIC is strong in asset, growth, and profitability, and relatively weak in dividend. Furthermore, HORIZON THERAPEUTICS PUBLIC has a high health score of 9/10 due to its healthy cash flows and low debt levels, meaning the company is well-positioned to sustain operations in times of crisis. Based on this assessment, we have classified HORIZON THERAPEUTICS PUBLIC as a ‘rhino’—a type of company that has achieved moderate revenue or earnings growth. This makes it an attractive investment option for investors looking for steady returns from a dependable organization. Additionally, the company’s strong asset base and solid profitability provide added security to those seeking reliable returns and a safe investment. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the marketplace for Horizon Therapeutics PLC is intense with large companies such as Merck & Co Inc, AbbVie Inc, and Arrowhead Pharmaceuticals Inc all vying for a share of the market. While each company has its own strengths and weaknesses, Horizon Therapeutics PLC has been able to compete effectively by offering a differentiated product portfolio and a focus on customer service.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co is a publicly traded American pharmaceutical company with a market capitalization of over $259 billion as of early 2021. The company develops and manufactures a wide range of prescription and over-the-counter medications, vaccines, and animal health products. Merck has been in operation for over a century and a half and is one of the largest pharmaceutical companies in the world. The company’s products are available in over 140 countries. Merck’s revenues totaled nearly $50 billion in 2020. The company’s return on equity was over 27% in 2020.
AbbVie Inc is a pharmaceutical company with a market cap of 269.09B as of 2022. It has a Return on Equity of 69.45%. The company focuses on the discovery, development, manufacture and commercialization of pharmaceutical products. Its products include Humira, an anti-inflammatory biologic medicine used to treat autoimmune diseases; and Imbruvica, a small molecule kinase inhibitor used to treat certain blood cancers and chronic lymphocytic leukemia.
– Arrowhead Pharmaceuticals Inc ($NASDAQ:ARWR)
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of innovative medicines that treat intractable diseases by silencing the genes that cause them. The company’s market cap as of 2022 is 3.24B and its ROE is -22.01%. Arrowhead is headquartered in Pasadena, California.
HORIZON THERAPEUTICS PUBLIC reported their FY2023 Q2 earnings results on June 30 2023. Total revenue grew by 7.8% to USD 945.0 million, while net income rose by a remarkable 108.4% to USD 127.1 million year-over-year. This is a promising sign for investors, indicating that HORIZON THERAPEUTICS PUBLIC is performing well and its financials are healthy.
Additionally, the company’s strong revenue growth shows it is on track to achieve its financial goals for the year and beyond. Investors should keep an eye out for future updates from HORIZON THERAPEUTICS PUBLIC to ensure it remains a stable and profitable investment.